Lindsey E. Roeker, MD

Senior Associate Consultant
Division of Hematology, Mayo Clinic

Poster(s):

• 1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi

• 1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study

• 1601 - Central Nervous System Involvement in Patients with Richter Transformation

• 1712 - Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• 1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study